Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 78,127 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 78,127 shares of Hims & Hers Health stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the sale, the chief executive officer now owns 109,956 shares of the company’s stock, valued at $3,256,896.72. The trade was a 41.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44.
• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.33, for a total transaction of $747,375.11.

Hims & Hers Health Trading Down 0.4 %

Hims & Hers Health stock opened at $31.12 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of 70.73 and a beta of 1.25. The firm has a 50 day moving average of $25.27 and a 200 day moving average of $21.14.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC lifted its holdings in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new position in Hims & Hers Health in the 2nd quarter worth approximately $111,000. CWM LLC grew its holdings in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Finally, Quarry LP raised its position in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Morgan Stanley started coverage on Hims & Hers Health in a report on Tuesday. They issued an “overweight” rating and a $42.00 target price on the stock. TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $22.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.